US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., according to sources familiar with the matter. This review is part of a broader government effort to assess spending on messenger RNA-based vaccines, the technology behind Moderna’s successful Covid vaccine. The contract for the bird flu vaccine was granted in the final days of the Biden administration, causing Moderna’s stock to surge 13% in the two days following the Jan. 17 announcement.
